Necrotizing biliary pancreatitis: time for cholecystectomy
- Disease/Condition
- Surgery
- Intervention type
- procedure
- Primary sponsor
- Mongi Slim university Hospital LaMarsa
- Funder
- Yes
- Location
- Tunisia
- Phase
- Not Applicable
- Start date
- Jun 05, 2023
- End date
- Jan 01, 1900
Acute necrotizing or necrotic-hemorrhagic pancreatitis accounts for 10-25% of all forms of acute pancreatitis, with High mortality and morbidity due to Multi-visceral failure syndrome and Superinfection of necrosis.Biliary origin most frequent in TUNISIATime for cholecystectomy is a controversial subject, There is No consensus with a high level of evidenceWe classically wait the ad integrum restitution of flows (about 3 months) to do the cholecystectomy, but in this time many patients develop recurrent pancreatitis, which is usually more severe before undergoing cholecystectomy. We propose to conduct a randomised, single-blind, unilateral controlled trial to assess the safety of early cholecystectomy in acute necrotising pancreatitis compared with late cholecystectomy. o Treatment tested (Group A): early cholecystectomy o Control group (Group B): delayed cholecystectomy Early cholecystectomy = during the same hospitalisation (within 15 days of symptomatology). Delayed cholecystectomy = after restitution ad integrum of the necrosis flows.Our Primary endpoint:perioperative complications (hemorrhage, biliary wound and superinfection of necrosis flows)
- Registry
- Pan Africa Clinical Trials Registry
- Trial ID
- PACTR202306789614899
- Type
- Non-Device Trial
Access comprehensive clinical trial information for PACTR202306789614899 through Pure Global AI's free database. This Not Applicable trial is sponsored by Mongi Slim university Hospital LaMarsa and is currently Recruiting. The study focuses on Surgery.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.